AI assistant
UroGen Pharma Ltd. — Director's Dealing 2025
Nov 20, 2025
32312_dirs_2025-11-20_9c4b7c0b-784e-40f0-8a1d-36723f4768e8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2025-11-19
Reporting Person: Schoenberg Mark (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-11-19 | Ordinary Shares | S | 10000 | $25 | Disposed | 139025 | Direct |
Footnotes
F1: Transaction made pursuant to duly adopted trading plan under Rule 10b5-1(c). Adoption date of referenced 10b5-1(c) plan is: 08-15-2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 and $25.02. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.